Dry Eye Syndromes Clinical Trial
Official title:
The Expression Levels of Diadenosine Polyphosphates and Mucin in Mechanical Stress-related Ocular Surface Disorders
Dry eye disease, ocular graft-versus-host disease (GVHD), and superior limbic
keratoconjunctivitis (SLK) are all ocular surface disorders which mostly involve the outer
surface of the eye. Many of the ocular surface disorders may result from or be aggravated by
the mechanical stress from eyelid blinking. Specifically, SLK is an inflammatory ocular
surface disorder characterizing by redundant superior bulbar conjunctiva. Since redundant
superior bulbar conjunctiva can cause a significant mechanical force during eyelid blinking,
we found that conjunctival resection with Tenon's capsule excision is helpful in relieving
the symptoms of SLK patients. Therapeutic contact lens, protecting the ocular surface from
the microtrauma between eyelid and ocular surface, is also an effective treatment for severe
dry eye disease, ocular GVHD, and SLK. Although shearing force/mechanical stress has been
studied in many different tissues and disease entities, the impact of shearing force over
ocular surface is still unclear.
While the importance of mechanical stress in ocular surface disorder has been reported, the
specific molecule involving the pathogenesis is still unknown. Diadenosine polyphosphates are
a family of dinucleotides. They can enhance tear secretion and increase corneal wound healing
rate from previous reports. Shear-stress stimuli was also noted to be able to induce
diadenosine polyphosphates releasing from human corneal epithelium. In addition, mucin, one
of the three components of tear film, has been greatly emphasized in the pathogenesis of dry
eye disease. There are also some reports about the shearing force compensating the mucin
contents in the inflammatory lung/bowel diseases. If diadenosine polyphosphates or mucin
indeed play a role in mechanical stress-related ocular surface disorders, it will be a
promising therapeutic targeting in the future.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - age 18 years or older - diagnosis of dry eye disease, ocular GVHD, and SLK - patients who ever received topical medications, including artificial tears and topical steroids, at least 3 months, but refractory to the treatment - absence of new systemic immunosuppressive medications within 1 month Exclusion Criteria: - pregnancy - absolute neutrophil count less than 1000/mL - known hypersensitivity or allergy to contact lens care products - treatment with scleral lenses within the previous 3 months - evidence of any active infection in the eyes - receiving any ocular surgeries within the previous 3 months |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taipei Tzu Chi Hospital | New Taipei City |
Lead Sponsor | Collaborator |
---|---|
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | adenosine polyphosphate level before treatment | identify the levels of adenosine polyphosphate via High Performance Liquid Chromatography (HPLC) between groups | before treatment | |
Primary | mucin level before treatment | identify the levels of mucin via ELISA between groups | before treatment | |
Secondary | adenosine polyphosphate after treatment | identify the levels of adenosine polyphosphate via HPLC between groups | post-treatment one month, three months and six months | |
Secondary | mucin after treatment | identify the levels of mucin via ELISA between groups | post-treatment one month, three months and six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Recruiting |
NCT04701086 -
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
|
N/A | |
Active, not recruiting |
NCT03697876 -
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
|
Phase 1 | |
Terminated |
NCT02815293 -
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT02910713 -
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
|
N/A | |
Completed |
NCT04104997 -
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
|
Phase 1 | |
Recruiting |
NCT02595606 -
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
|
Phase 4 | |
Completed |
NCT01711424 -
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
|
N/A | |
Completed |
NCT01015209 -
Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
|
Phase 1 | |
Completed |
NCT01202747 -
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
|
Phase 2/Phase 3 | |
Completed |
NCT00969280 -
Acupuncture for Dry Eye Syndrome
|
Phase 3 | |
Completed |
NCT01496482 -
Comparison of Evaporimetry With the Established Methods of Tear Film Measurement
|
N/A | |
Completed |
NCT00739713 -
Effects of Sea Buckthorn Oil on Dry Eye
|
N/A | |
Completed |
NCT00756678 -
Efficacy and Acceptability of Two Lubricant Eye Drops
|
Phase 4 | |
Completed |
NCT00370747 -
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00349440 -
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
|
Phase 4 | |
Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT02871440 -
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT05042960 -
Computer Screen Properties Study
|
N/A |